Review



foxo3a  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Cell Signaling Technology Inc foxo3a
    Foxo3a, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 879 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/foxo3a/FoxO3a+Rabbit+mAb/pm42882471-83-46-47
    Average 96 stars, based on 879 article reviews
    foxo3a - by Bioz Stars, 2026-11
    96/100 stars

    Images

    Related Articles

    Incubation:

    Article Title: SP/NK-1 pathogenic signaling drives doxorubicin nephrotoxicity: Novel therapeutic role of MK-0869 via modulation of α-Klotho, RAS, and Wnt/β-catenin trajectories.
    Article Snippet: Doxorubicin (Dox) is a cornerstone chemotherapeutic agent whose clinical use is limited by nephrotoxicity driven by oxidative stress, renin-angiotensin system (RAS) imbalance, activation of the profibrotic Wnt/β-catenin pathway, and suppression of the renoprotective protein α-Klotho.. Substance P (SP) signaling through the neurokinin-1 (NK-1) receptor is a mediator of inflammatory injury; however, its role in Dox-induced nephrotoxicity remains unexplored.. Therefore, we investigated whether pharmacological blockade of the NK-1 receptor with MK-0869 could alleviate Dox-induced nephrotoxicity and modulate α-Klotho–associated antioxidant and

    Control:

    Article Title: Muscle Loss Driven by Extracellular Signal-Regulated Kinase Suppression via β-Adrenergic Activation in High-Normal Catecholamine Status
    Article Snippet: Following three additional washes with 1× TBST, protein bands were visualized using enhanced chemiluminescence solution and quantified using the ChemiDoc imaging system (Thermo Fisher, Waltham, MA, USA; iBright CL1500). .. Primary antibodies used included phospho-PKAc (Cell Signaling Technology, Danvers, MA, USA; 5661), PKA (Cell Signaling Technology, 5842), phospho-ERK (Cell Signaling Technology, 4377), ERK (Santa Cruz Biotechnology, sc-94), phospho-AKT (Cell signaling Technology, 9271), AKT (Cell signaling Technology, 4691), phospho-p38 (Cell signaling Technology, 9211), p38 (Cell signaling Technology, 9212), phospho-forkhead box O3a (phospho-FOXO3a; Cell signaling Technology, 14724), FOXO3a (Cell signaling Technology, 12829), phospho-FOXO1 (Cell signaling Technology, 9461), FOXO1 (Cell signaling Technology, 2880), and β-actin (sc-47778) as a loading control. .. To evaluate myogenesis and myotube formation, the Incucyte Live-Cell Analysis System (Sartorius, Göttingen, Germany) was employed.

    Cell-Signaling:

    Article Title: High Fat Diet and Obesity Each Increase Tumor Cell Proliferation and Muscle Wasting in Experimental Cancer Cachexia
    Article Snippet: Protein bands were visualized by incubation with enhanced chemiluminescence (Pierce Super Signal Pico or Dura, Thermo Fisher Scientific, Suwanee, GA) and exposure to film. .. Antibodies used were: pSTAT3-Y705 (9145), STAT3 (9132), p-AKT-S473 (4060), AKT (4685), p-Foxo3a-S381/321 (9465), Foxo3a (2497), and GAPDH (2118) from Cell Signaling Technology (Beverly, MA); and IL-6 (MABF41) from EMD Millipore (Billerica, MA). ..

    Article Title: Veronicastrum sibiricum (L.) Pennell extract alleviates inflammation-induced muscle atrophy through NLRP3 inflammasome regulation and mitochondrial function restoration
    Article Snippet: p-Akt , Rabbit monoclonal , 9271 , Cell Signaling Technology, Inc. , 1:1,000. .. Foxo3a , Rabbit monoclonal , 2497 , Cell Signaling Technology, Inc. , 1:1,000. .. p-Foxo3a , Rabbit monoclonal , 5538 , Cell Signaling Technology, Inc. , 1:1,000.

    Article Title: Distinct OA:PA Ratios Generate Discrete Hepatocellular Phenotypes in HepG2 Cells.
    Article Snippet: Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad, Hercules, CA, USA), blocked with 5% skim milk for 1 h, and incubated with primary antibodies overnight at 4 ◦C. .. Primary antibodies (all 1: 1000): AMPKα [Cell Signaling Technology (CST, Danvers, MA, USA) #2532], BAX (CST, Cat. No. 5023), BCL-2 (CST, Cat. No. 15071), BiP (CST, Cat. No. 3177S), CHOP (CST, Cat. No. 2895S), COX-2 (Abcam, Cambridge, UK, Cat. No. ab283574), FASN (CST, Cat. No. 3180S), FoxO3a (CST, Cat. No. 2497S), IL-1β (CST, https://doi.org/10.3390/cells15191774 Cat. No. 12242S), LC3A/B (CST, Cat. No. 4108S), mTOR (CST, Cat. No. 2983), NF-κB p65 (Abcam, Cat. No. ab32536), p62/SQSTM1 (CST, Cat. No. 5114S), phospho-AMPKα Thr172 (CST, Cat. No. 2535), phospho-FoxO3a Ser253 (CST, Cat. No. 9466S), phospho-mTOR Ser2448 (CST, Cat. No. 2971), phospho-NF-κB p65 Ser536 (CST, Cat. No. 3033S), SREBP-1 (CST, Cat. No. 95879S), and TNF-α (CST, Cat. No. 3707S). .. GAPDH–horseradish peroxidase (HRP) (ServiceBio, Wuhan, China, Cat. No. ZB15004-HRP; 1:5000) served as loading control for the main figure panels; recombinant anti-β-actin–HRP (ServiceBio, Cat. No. ZB15001HRP; 1:5000) served as loading control for the BAX/BCL-2 blots (Supplementary Figure S1).



    Similar Products

    94
    Bioss foxo3a
    Foxo3a, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/foxo3a/FOXO3A+Polyclonal+Antibody/pm42789189-98-39-42
    Average 94 stars, based on 1 article reviews
    foxo3a - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    96
    Proteintech antibodies against foxo3a
    Antibodies Against Foxo3a, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/foxo3a/FOXO3A+Antibody/pm42915814-21-0-8
    Average 96 stars, based on 1 article reviews
    antibodies against foxo3a - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    Proteintech anti foxo3
    Anti Foxo3, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/foxo3a/FOXO3A+Antibody/pm42893935-313-0-26
    Average 96 stars, based on 1 article reviews
    anti foxo3 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    Proteintech foxo3a
    TRX2 interacts with <t>FOXO3a</t> through a redox‐sensitive Cys90–Cys31 interface and restrains FOXO3a nuclear translocation. A) Liquid chromatography–tandem mass spectrometry (LC‐MS/MS) analysis identifying FOXO3a as a TRX2‐binding partner. The representative MS/MS spectrum shows the peptide sequences of FOXO3a associated with TRX2. B) Structured illumination microscopy (SIM) images and 3D reconstructions showing colocalization of TRX2 (red) and FOXO3a (green) in HEK293T cells. Mitochondria and nuclei were labeled with MitoTracker (magenta) and Hoechst (blue), respectively. Scale bars, 2 µm. C) Proteinase K protection assay in isolated mitochondria treated with proteinase K in the presence or absence of Triton X‐100. VDAC1 and HSP60 served as mitochondrial outer membrane and matrix markers, respectively. D) Representative fluorescence images of HUVECs transfected with control siRNA (siCon) or TRX2‐targeting siRNA (siTRX2) and subjected to Duolink proximity ligation assay (PLA) using antibodies against TRX2 and FOXO3a. Green puncta represent PLA signals indicating close proximity between TRX2 and FOXO3a. Mitochondria were labeled with MitoTracker (magenta), and nuclei were counterstained with Hoechst (blue) (n = 3). Scale bars, 5 µm. E) Representative immunofluorescence images of distal femoral sections from 12‐week‐old Trx2 WT and Trx2 ECKO mice stained for CD31 (red), FOXO3a (green), and Hoechst (blue) (n = 3). Dashed boxes indicate the regions shown at higher magnification, with the corresponding single‐channel images presented on the right. Scale bars: 50 µm (overview images) and 20 µm (magnified and single‐channel images). F) Co‐immunoprecipitation (Co‐IP) assay in HEK293T cells transfected with FOXO3a‐Flag and different TRX2‐HA constructs, including wild‐type (WT), C90S, C93S, and C90/93S mutants, showing the requirement of TRX2 active‐site cysteines for FOXO3a binding. G) Molecular docking illustrating the predicted interface of the TRX2‐FOXO3a complex. The enlarged view shows the spatial proximity of TRX2 Cys90/Cys93 and FOXO3a Cys31. H) Co‐IP assay showing the interaction between endogenous TRX2 and FOXO3a‐Flag, including WT and cysteine‐mutant FOXO3a constructs. I) Co‐IP assay showing that the TRX2–FOXO3a interaction is sensitive to oxidative stress induced by hydrogen peroxide (H 2 O 2 ). J, K) Western blot analysis of nucleocytoplasmic fractionation (J) and representative immunofluorescence images (K) showing the effect of siCon or siTRX2 treatment on FOXO3a subcellular distribution. Lamin B1 and GAPDH served as nuclear and cytosolic markers, respectively. Scale bars: 5 µm. L) Quantification of the nuclear fraction of FOXO3a corresponding to the immunofluorescence images in (K) (n = 5, with three technical replicates). M) Proposed model summarizing the mechanism by which TRX2 regulates FOXO3a subcellular localization. Source data for the unedited raw immunoblots shown in Figure . All quantitative data are presented as means ± SEM. Statistical significance was determined by a two‐tailed unpaired Student's t ‐test. **** p < 0.0001.
    Foxo3a, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/foxo3a/FOXO3A+Antibody/pmc13676988-304-21-23
    Average 96 stars, based on 1 article reviews
    foxo3a - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc foxo3a
    TRX2 interacts with <t>FOXO3a</t> through a redox‐sensitive Cys90–Cys31 interface and restrains FOXO3a nuclear translocation. A) Liquid chromatography–tandem mass spectrometry (LC‐MS/MS) analysis identifying FOXO3a as a TRX2‐binding partner. The representative MS/MS spectrum shows the peptide sequences of FOXO3a associated with TRX2. B) Structured illumination microscopy (SIM) images and 3D reconstructions showing colocalization of TRX2 (red) and FOXO3a (green) in HEK293T cells. Mitochondria and nuclei were labeled with MitoTracker (magenta) and Hoechst (blue), respectively. Scale bars, 2 µm. C) Proteinase K protection assay in isolated mitochondria treated with proteinase K in the presence or absence of Triton X‐100. VDAC1 and HSP60 served as mitochondrial outer membrane and matrix markers, respectively. D) Representative fluorescence images of HUVECs transfected with control siRNA (siCon) or TRX2‐targeting siRNA (siTRX2) and subjected to Duolink proximity ligation assay (PLA) using antibodies against TRX2 and FOXO3a. Green puncta represent PLA signals indicating close proximity between TRX2 and FOXO3a. Mitochondria were labeled with MitoTracker (magenta), and nuclei were counterstained with Hoechst (blue) (n = 3). Scale bars, 5 µm. E) Representative immunofluorescence images of distal femoral sections from 12‐week‐old Trx2 WT and Trx2 ECKO mice stained for CD31 (red), FOXO3a (green), and Hoechst (blue) (n = 3). Dashed boxes indicate the regions shown at higher magnification, with the corresponding single‐channel images presented on the right. Scale bars: 50 µm (overview images) and 20 µm (magnified and single‐channel images). F) Co‐immunoprecipitation (Co‐IP) assay in HEK293T cells transfected with FOXO3a‐Flag and different TRX2‐HA constructs, including wild‐type (WT), C90S, C93S, and C90/93S mutants, showing the requirement of TRX2 active‐site cysteines for FOXO3a binding. G) Molecular docking illustrating the predicted interface of the TRX2‐FOXO3a complex. The enlarged view shows the spatial proximity of TRX2 Cys90/Cys93 and FOXO3a Cys31. H) Co‐IP assay showing the interaction between endogenous TRX2 and FOXO3a‐Flag, including WT and cysteine‐mutant FOXO3a constructs. I) Co‐IP assay showing that the TRX2–FOXO3a interaction is sensitive to oxidative stress induced by hydrogen peroxide (H 2 O 2 ). J, K) Western blot analysis of nucleocytoplasmic fractionation (J) and representative immunofluorescence images (K) showing the effect of siCon or siTRX2 treatment on FOXO3a subcellular distribution. Lamin B1 and GAPDH served as nuclear and cytosolic markers, respectively. Scale bars: 5 µm. L) Quantification of the nuclear fraction of FOXO3a corresponding to the immunofluorescence images in (K) (n = 5, with three technical replicates). M) Proposed model summarizing the mechanism by which TRX2 regulates FOXO3a subcellular localization. Source data for the unedited raw immunoblots shown in Figure . All quantitative data are presented as means ± SEM. Statistical significance was determined by a two‐tailed unpaired Student's t ‐test. **** p < 0.0001.
    Foxo3a, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/foxo3a/FoxO3a+Rabbit+mAb/pm42882471-83-46-47
    Average 96 stars, based on 1 article reviews
    foxo3a - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc phospho foxo3a ser253
    TRX2 interacts with <t>FOXO3a</t> through a redox‐sensitive Cys90–Cys31 interface and restrains FOXO3a nuclear translocation. A) Liquid chromatography–tandem mass spectrometry (LC‐MS/MS) analysis identifying FOXO3a as a TRX2‐binding partner. The representative MS/MS spectrum shows the peptide sequences of FOXO3a associated with TRX2. B) Structured illumination microscopy (SIM) images and 3D reconstructions showing colocalization of TRX2 (red) and FOXO3a (green) in HEK293T cells. Mitochondria and nuclei were labeled with MitoTracker (magenta) and Hoechst (blue), respectively. Scale bars, 2 µm. C) Proteinase K protection assay in isolated mitochondria treated with proteinase K in the presence or absence of Triton X‐100. VDAC1 and HSP60 served as mitochondrial outer membrane and matrix markers, respectively. D) Representative fluorescence images of HUVECs transfected with control siRNA (siCon) or TRX2‐targeting siRNA (siTRX2) and subjected to Duolink proximity ligation assay (PLA) using antibodies against TRX2 and FOXO3a. Green puncta represent PLA signals indicating close proximity between TRX2 and FOXO3a. Mitochondria were labeled with MitoTracker (magenta), and nuclei were counterstained with Hoechst (blue) (n = 3). Scale bars, 5 µm. E) Representative immunofluorescence images of distal femoral sections from 12‐week‐old Trx2 WT and Trx2 ECKO mice stained for CD31 (red), FOXO3a (green), and Hoechst (blue) (n = 3). Dashed boxes indicate the regions shown at higher magnification, with the corresponding single‐channel images presented on the right. Scale bars: 50 µm (overview images) and 20 µm (magnified and single‐channel images). F) Co‐immunoprecipitation (Co‐IP) assay in HEK293T cells transfected with FOXO3a‐Flag and different TRX2‐HA constructs, including wild‐type (WT), C90S, C93S, and C90/93S mutants, showing the requirement of TRX2 active‐site cysteines for FOXO3a binding. G) Molecular docking illustrating the predicted interface of the TRX2‐FOXO3a complex. The enlarged view shows the spatial proximity of TRX2 Cys90/Cys93 and FOXO3a Cys31. H) Co‐IP assay showing the interaction between endogenous TRX2 and FOXO3a‐Flag, including WT and cysteine‐mutant FOXO3a constructs. I) Co‐IP assay showing that the TRX2–FOXO3a interaction is sensitive to oxidative stress induced by hydrogen peroxide (H 2 O 2 ). J, K) Western blot analysis of nucleocytoplasmic fractionation (J) and representative immunofluorescence images (K) showing the effect of siCon or siTRX2 treatment on FOXO3a subcellular distribution. Lamin B1 and GAPDH served as nuclear and cytosolic markers, respectively. Scale bars: 5 µm. L) Quantification of the nuclear fraction of FOXO3a corresponding to the immunofluorescence images in (K) (n = 5, with three technical replicates). M) Proposed model summarizing the mechanism by which TRX2 regulates FOXO3a subcellular localization. Source data for the unedited raw immunoblots shown in Figure . All quantitative data are presented as means ± SEM. Statistical significance was determined by a two‐tailed unpaired Student's t ‐test. **** p < 0.0001.
    Phospho Foxo3a Ser253, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/foxo3a/Phospho-FoxO3a+(Ser253)+Antibody/pm42882471-83-84-86
    Average 96 stars, based on 1 article reviews
    phospho foxo3a ser253 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc anti foxo3
    TRX2 interacts with <t>FOXO3a</t> through a redox‐sensitive Cys90–Cys31 interface and restrains FOXO3a nuclear translocation. A) Liquid chromatography–tandem mass spectrometry (LC‐MS/MS) analysis identifying FOXO3a as a TRX2‐binding partner. The representative MS/MS spectrum shows the peptide sequences of FOXO3a associated with TRX2. B) Structured illumination microscopy (SIM) images and 3D reconstructions showing colocalization of TRX2 (red) and FOXO3a (green) in HEK293T cells. Mitochondria and nuclei were labeled with MitoTracker (magenta) and Hoechst (blue), respectively. Scale bars, 2 µm. C) Proteinase K protection assay in isolated mitochondria treated with proteinase K in the presence or absence of Triton X‐100. VDAC1 and HSP60 served as mitochondrial outer membrane and matrix markers, respectively. D) Representative fluorescence images of HUVECs transfected with control siRNA (siCon) or TRX2‐targeting siRNA (siTRX2) and subjected to Duolink proximity ligation assay (PLA) using antibodies against TRX2 and FOXO3a. Green puncta represent PLA signals indicating close proximity between TRX2 and FOXO3a. Mitochondria were labeled with MitoTracker (magenta), and nuclei were counterstained with Hoechst (blue) (n = 3). Scale bars, 5 µm. E) Representative immunofluorescence images of distal femoral sections from 12‐week‐old Trx2 WT and Trx2 ECKO mice stained for CD31 (red), FOXO3a (green), and Hoechst (blue) (n = 3). Dashed boxes indicate the regions shown at higher magnification, with the corresponding single‐channel images presented on the right. Scale bars: 50 µm (overview images) and 20 µm (magnified and single‐channel images). F) Co‐immunoprecipitation (Co‐IP) assay in HEK293T cells transfected with FOXO3a‐Flag and different TRX2‐HA constructs, including wild‐type (WT), C90S, C93S, and C90/93S mutants, showing the requirement of TRX2 active‐site cysteines for FOXO3a binding. G) Molecular docking illustrating the predicted interface of the TRX2‐FOXO3a complex. The enlarged view shows the spatial proximity of TRX2 Cys90/Cys93 and FOXO3a Cys31. H) Co‐IP assay showing the interaction between endogenous TRX2 and FOXO3a‐Flag, including WT and cysteine‐mutant FOXO3a constructs. I) Co‐IP assay showing that the TRX2–FOXO3a interaction is sensitive to oxidative stress induced by hydrogen peroxide (H 2 O 2 ). J, K) Western blot analysis of nucleocytoplasmic fractionation (J) and representative immunofluorescence images (K) showing the effect of siCon or siTRX2 treatment on FOXO3a subcellular distribution. Lamin B1 and GAPDH served as nuclear and cytosolic markers, respectively. Scale bars: 5 µm. L) Quantification of the nuclear fraction of FOXO3a corresponding to the immunofluorescence images in (K) (n = 5, with three technical replicates). M) Proposed model summarizing the mechanism by which TRX2 regulates FOXO3a subcellular localization. Source data for the unedited raw immunoblots shown in Figure . All quantitative data are presented as means ± SEM. Statistical significance was determined by a two‐tailed unpaired Student's t ‐test. **** p < 0.0001.
    Anti Foxo3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/foxo3a/FoxO3a+Rabbit+mAb/pm42869303-137-22-23
    Average 96 stars, based on 1 article reviews
    anti foxo3 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    Proteintech foxo3 primary antibody
    TRX2 interacts with <t>FOXO3a</t> through a redox‐sensitive Cys90–Cys31 interface and restrains FOXO3a nuclear translocation. A) Liquid chromatography–tandem mass spectrometry (LC‐MS/MS) analysis identifying FOXO3a as a TRX2‐binding partner. The representative MS/MS spectrum shows the peptide sequences of FOXO3a associated with TRX2. B) Structured illumination microscopy (SIM) images and 3D reconstructions showing colocalization of TRX2 (red) and FOXO3a (green) in HEK293T cells. Mitochondria and nuclei were labeled with MitoTracker (magenta) and Hoechst (blue), respectively. Scale bars, 2 µm. C) Proteinase K protection assay in isolated mitochondria treated with proteinase K in the presence or absence of Triton X‐100. VDAC1 and HSP60 served as mitochondrial outer membrane and matrix markers, respectively. D) Representative fluorescence images of HUVECs transfected with control siRNA (siCon) or TRX2‐targeting siRNA (siTRX2) and subjected to Duolink proximity ligation assay (PLA) using antibodies against TRX2 and FOXO3a. Green puncta represent PLA signals indicating close proximity between TRX2 and FOXO3a. Mitochondria were labeled with MitoTracker (magenta), and nuclei were counterstained with Hoechst (blue) (n = 3). Scale bars, 5 µm. E) Representative immunofluorescence images of distal femoral sections from 12‐week‐old Trx2 WT and Trx2 ECKO mice stained for CD31 (red), FOXO3a (green), and Hoechst (blue) (n = 3). Dashed boxes indicate the regions shown at higher magnification, with the corresponding single‐channel images presented on the right. Scale bars: 50 µm (overview images) and 20 µm (magnified and single‐channel images). F) Co‐immunoprecipitation (Co‐IP) assay in HEK293T cells transfected with FOXO3a‐Flag and different TRX2‐HA constructs, including wild‐type (WT), C90S, C93S, and C90/93S mutants, showing the requirement of TRX2 active‐site cysteines for FOXO3a binding. G) Molecular docking illustrating the predicted interface of the TRX2‐FOXO3a complex. The enlarged view shows the spatial proximity of TRX2 Cys90/Cys93 and FOXO3a Cys31. H) Co‐IP assay showing the interaction between endogenous TRX2 and FOXO3a‐Flag, including WT and cysteine‐mutant FOXO3a constructs. I) Co‐IP assay showing that the TRX2–FOXO3a interaction is sensitive to oxidative stress induced by hydrogen peroxide (H 2 O 2 ). J, K) Western blot analysis of nucleocytoplasmic fractionation (J) and representative immunofluorescence images (K) showing the effect of siCon or siTRX2 treatment on FOXO3a subcellular distribution. Lamin B1 and GAPDH served as nuclear and cytosolic markers, respectively. Scale bars: 5 µm. L) Quantification of the nuclear fraction of FOXO3a corresponding to the immunofluorescence images in (K) (n = 5, with three technical replicates). M) Proposed model summarizing the mechanism by which TRX2 regulates FOXO3a subcellular localization. Source data for the unedited raw immunoblots shown in Figure . All quantitative data are presented as means ± SEM. Statistical significance was determined by a two‐tailed unpaired Student's t ‐test. **** p < 0.0001.
    Foxo3 Primary Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/foxo3a/FOXO3A+Antibody/pm42860232-110-12-16
    Average 96 stars, based on 1 article reviews
    foxo3 primary antibody - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    93
    Addgene inc pcdna3 flag foxo3a fkhrl1 aaa
    TRX2 interacts with <t>FOXO3a</t> through a redox‐sensitive Cys90–Cys31 interface and restrains FOXO3a nuclear translocation. A) Liquid chromatography–tandem mass spectrometry (LC‐MS/MS) analysis identifying FOXO3a as a TRX2‐binding partner. The representative MS/MS spectrum shows the peptide sequences of FOXO3a associated with TRX2. B) Structured illumination microscopy (SIM) images and 3D reconstructions showing colocalization of TRX2 (red) and FOXO3a (green) in HEK293T cells. Mitochondria and nuclei were labeled with MitoTracker (magenta) and Hoechst (blue), respectively. Scale bars, 2 µm. C) Proteinase K protection assay in isolated mitochondria treated with proteinase K in the presence or absence of Triton X‐100. VDAC1 and HSP60 served as mitochondrial outer membrane and matrix markers, respectively. D) Representative fluorescence images of HUVECs transfected with control siRNA (siCon) or TRX2‐targeting siRNA (siTRX2) and subjected to Duolink proximity ligation assay (PLA) using antibodies against TRX2 and FOXO3a. Green puncta represent PLA signals indicating close proximity between TRX2 and FOXO3a. Mitochondria were labeled with MitoTracker (magenta), and nuclei were counterstained with Hoechst (blue) (n = 3). Scale bars, 5 µm. E) Representative immunofluorescence images of distal femoral sections from 12‐week‐old Trx2 WT and Trx2 ECKO mice stained for CD31 (red), FOXO3a (green), and Hoechst (blue) (n = 3). Dashed boxes indicate the regions shown at higher magnification, with the corresponding single‐channel images presented on the right. Scale bars: 50 µm (overview images) and 20 µm (magnified and single‐channel images). F) Co‐immunoprecipitation (Co‐IP) assay in HEK293T cells transfected with FOXO3a‐Flag and different TRX2‐HA constructs, including wild‐type (WT), C90S, C93S, and C90/93S mutants, showing the requirement of TRX2 active‐site cysteines for FOXO3a binding. G) Molecular docking illustrating the predicted interface of the TRX2‐FOXO3a complex. The enlarged view shows the spatial proximity of TRX2 Cys90/Cys93 and FOXO3a Cys31. H) Co‐IP assay showing the interaction between endogenous TRX2 and FOXO3a‐Flag, including WT and cysteine‐mutant FOXO3a constructs. I) Co‐IP assay showing that the TRX2–FOXO3a interaction is sensitive to oxidative stress induced by hydrogen peroxide (H 2 O 2 ). J, K) Western blot analysis of nucleocytoplasmic fractionation (J) and representative immunofluorescence images (K) showing the effect of siCon or siTRX2 treatment on FOXO3a subcellular distribution. Lamin B1 and GAPDH served as nuclear and cytosolic markers, respectively. Scale bars: 5 µm. L) Quantification of the nuclear fraction of FOXO3a corresponding to the immunofluorescence images in (K) (n = 5, with three technical replicates). M) Proposed model summarizing the mechanism by which TRX2 regulates FOXO3a subcellular localization. Source data for the unedited raw immunoblots shown in Figure . All quantitative data are presented as means ± SEM. Statistical significance was determined by a two‐tailed unpaired Student's t ‐test. **** p < 0.0001.
    Pcdna3 Flag Foxo3a Fkhrl1 Aaa, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/foxo3a/1319+pcDNA3+flag+FKHRL1+AAA+(Plasmid+%2310709)/pm42778596-478-18-22
    Average 93 stars, based on 1 article reviews
    pcdna3 flag foxo3a fkhrl1 aaa - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    94
    Proteintech phospho foxo3a ser315
    TRX2 interacts with <t>FOXO3a</t> through a redox‐sensitive Cys90–Cys31 interface and restrains FOXO3a nuclear translocation. A) Liquid chromatography–tandem mass spectrometry (LC‐MS/MS) analysis identifying FOXO3a as a TRX2‐binding partner. The representative MS/MS spectrum shows the peptide sequences of FOXO3a associated with TRX2. B) Structured illumination microscopy (SIM) images and 3D reconstructions showing colocalization of TRX2 (red) and FOXO3a (green) in HEK293T cells. Mitochondria and nuclei were labeled with MitoTracker (magenta) and Hoechst (blue), respectively. Scale bars, 2 µm. C) Proteinase K protection assay in isolated mitochondria treated with proteinase K in the presence or absence of Triton X‐100. VDAC1 and HSP60 served as mitochondrial outer membrane and matrix markers, respectively. D) Representative fluorescence images of HUVECs transfected with control siRNA (siCon) or TRX2‐targeting siRNA (siTRX2) and subjected to Duolink proximity ligation assay (PLA) using antibodies against TRX2 and FOXO3a. Green puncta represent PLA signals indicating close proximity between TRX2 and FOXO3a. Mitochondria were labeled with MitoTracker (magenta), and nuclei were counterstained with Hoechst (blue) (n = 3). Scale bars, 5 µm. E) Representative immunofluorescence images of distal femoral sections from 12‐week‐old Trx2 WT and Trx2 ECKO mice stained for CD31 (red), FOXO3a (green), and Hoechst (blue) (n = 3). Dashed boxes indicate the regions shown at higher magnification, with the corresponding single‐channel images presented on the right. Scale bars: 50 µm (overview images) and 20 µm (magnified and single‐channel images). F) Co‐immunoprecipitation (Co‐IP) assay in HEK293T cells transfected with FOXO3a‐Flag and different TRX2‐HA constructs, including wild‐type (WT), C90S, C93S, and C90/93S mutants, showing the requirement of TRX2 active‐site cysteines for FOXO3a binding. G) Molecular docking illustrating the predicted interface of the TRX2‐FOXO3a complex. The enlarged view shows the spatial proximity of TRX2 Cys90/Cys93 and FOXO3a Cys31. H) Co‐IP assay showing the interaction between endogenous TRX2 and FOXO3a‐Flag, including WT and cysteine‐mutant FOXO3a constructs. I) Co‐IP assay showing that the TRX2–FOXO3a interaction is sensitive to oxidative stress induced by hydrogen peroxide (H 2 O 2 ). J, K) Western blot analysis of nucleocytoplasmic fractionation (J) and representative immunofluorescence images (K) showing the effect of siCon or siTRX2 treatment on FOXO3a subcellular distribution. Lamin B1 and GAPDH served as nuclear and cytosolic markers, respectively. Scale bars: 5 µm. L) Quantification of the nuclear fraction of FOXO3a corresponding to the immunofluorescence images in (K) (n = 5, with three technical replicates). M) Proposed model summarizing the mechanism by which TRX2 regulates FOXO3a subcellular localization. Source data for the unedited raw immunoblots shown in Figure . All quantitative data are presented as means ± SEM. Statistical significance was determined by a two‐tailed unpaired Student's t ‐test. **** p < 0.0001.
    Phospho Foxo3a Ser315, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/foxo3a/Phospho-FOXO3A+(Ser315)+Antibody/pm42778596-538-67-70
    Average 94 stars, based on 1 article reviews
    phospho foxo3a ser315 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    Image Search Results


    TRX2 interacts with FOXO3a through a redox‐sensitive Cys90–Cys31 interface and restrains FOXO3a nuclear translocation. A) Liquid chromatography–tandem mass spectrometry (LC‐MS/MS) analysis identifying FOXO3a as a TRX2‐binding partner. The representative MS/MS spectrum shows the peptide sequences of FOXO3a associated with TRX2. B) Structured illumination microscopy (SIM) images and 3D reconstructions showing colocalization of TRX2 (red) and FOXO3a (green) in HEK293T cells. Mitochondria and nuclei were labeled with MitoTracker (magenta) and Hoechst (blue), respectively. Scale bars, 2 µm. C) Proteinase K protection assay in isolated mitochondria treated with proteinase K in the presence or absence of Triton X‐100. VDAC1 and HSP60 served as mitochondrial outer membrane and matrix markers, respectively. D) Representative fluorescence images of HUVECs transfected with control siRNA (siCon) or TRX2‐targeting siRNA (siTRX2) and subjected to Duolink proximity ligation assay (PLA) using antibodies against TRX2 and FOXO3a. Green puncta represent PLA signals indicating close proximity between TRX2 and FOXO3a. Mitochondria were labeled with MitoTracker (magenta), and nuclei were counterstained with Hoechst (blue) (n = 3). Scale bars, 5 µm. E) Representative immunofluorescence images of distal femoral sections from 12‐week‐old Trx2 WT and Trx2 ECKO mice stained for CD31 (red), FOXO3a (green), and Hoechst (blue) (n = 3). Dashed boxes indicate the regions shown at higher magnification, with the corresponding single‐channel images presented on the right. Scale bars: 50 µm (overview images) and 20 µm (magnified and single‐channel images). F) Co‐immunoprecipitation (Co‐IP) assay in HEK293T cells transfected with FOXO3a‐Flag and different TRX2‐HA constructs, including wild‐type (WT), C90S, C93S, and C90/93S mutants, showing the requirement of TRX2 active‐site cysteines for FOXO3a binding. G) Molecular docking illustrating the predicted interface of the TRX2‐FOXO3a complex. The enlarged view shows the spatial proximity of TRX2 Cys90/Cys93 and FOXO3a Cys31. H) Co‐IP assay showing the interaction between endogenous TRX2 and FOXO3a‐Flag, including WT and cysteine‐mutant FOXO3a constructs. I) Co‐IP assay showing that the TRX2–FOXO3a interaction is sensitive to oxidative stress induced by hydrogen peroxide (H 2 O 2 ). J, K) Western blot analysis of nucleocytoplasmic fractionation (J) and representative immunofluorescence images (K) showing the effect of siCon or siTRX2 treatment on FOXO3a subcellular distribution. Lamin B1 and GAPDH served as nuclear and cytosolic markers, respectively. Scale bars: 5 µm. L) Quantification of the nuclear fraction of FOXO3a corresponding to the immunofluorescence images in (K) (n = 5, with three technical replicates). M) Proposed model summarizing the mechanism by which TRX2 regulates FOXO3a subcellular localization. Source data for the unedited raw immunoblots shown in Figure . All quantitative data are presented as means ± SEM. Statistical significance was determined by a two‐tailed unpaired Student's t ‐test. **** p < 0.0001.

    Journal: Advanced Science

    Article Title: Thioredoxin‐2 Alleviates Osteoporosis by Restraining FOXO3a Nuclear Translocation

    doi: 10.1002/advs.78304

    Figure Lengend Snippet: TRX2 interacts with FOXO3a through a redox‐sensitive Cys90–Cys31 interface and restrains FOXO3a nuclear translocation. A) Liquid chromatography–tandem mass spectrometry (LC‐MS/MS) analysis identifying FOXO3a as a TRX2‐binding partner. The representative MS/MS spectrum shows the peptide sequences of FOXO3a associated with TRX2. B) Structured illumination microscopy (SIM) images and 3D reconstructions showing colocalization of TRX2 (red) and FOXO3a (green) in HEK293T cells. Mitochondria and nuclei were labeled with MitoTracker (magenta) and Hoechst (blue), respectively. Scale bars, 2 µm. C) Proteinase K protection assay in isolated mitochondria treated with proteinase K in the presence or absence of Triton X‐100. VDAC1 and HSP60 served as mitochondrial outer membrane and matrix markers, respectively. D) Representative fluorescence images of HUVECs transfected with control siRNA (siCon) or TRX2‐targeting siRNA (siTRX2) and subjected to Duolink proximity ligation assay (PLA) using antibodies against TRX2 and FOXO3a. Green puncta represent PLA signals indicating close proximity between TRX2 and FOXO3a. Mitochondria were labeled with MitoTracker (magenta), and nuclei were counterstained with Hoechst (blue) (n = 3). Scale bars, 5 µm. E) Representative immunofluorescence images of distal femoral sections from 12‐week‐old Trx2 WT and Trx2 ECKO mice stained for CD31 (red), FOXO3a (green), and Hoechst (blue) (n = 3). Dashed boxes indicate the regions shown at higher magnification, with the corresponding single‐channel images presented on the right. Scale bars: 50 µm (overview images) and 20 µm (magnified and single‐channel images). F) Co‐immunoprecipitation (Co‐IP) assay in HEK293T cells transfected with FOXO3a‐Flag and different TRX2‐HA constructs, including wild‐type (WT), C90S, C93S, and C90/93S mutants, showing the requirement of TRX2 active‐site cysteines for FOXO3a binding. G) Molecular docking illustrating the predicted interface of the TRX2‐FOXO3a complex. The enlarged view shows the spatial proximity of TRX2 Cys90/Cys93 and FOXO3a Cys31. H) Co‐IP assay showing the interaction between endogenous TRX2 and FOXO3a‐Flag, including WT and cysteine‐mutant FOXO3a constructs. I) Co‐IP assay showing that the TRX2–FOXO3a interaction is sensitive to oxidative stress induced by hydrogen peroxide (H 2 O 2 ). J, K) Western blot analysis of nucleocytoplasmic fractionation (J) and representative immunofluorescence images (K) showing the effect of siCon or siTRX2 treatment on FOXO3a subcellular distribution. Lamin B1 and GAPDH served as nuclear and cytosolic markers, respectively. Scale bars: 5 µm. L) Quantification of the nuclear fraction of FOXO3a corresponding to the immunofluorescence images in (K) (n = 5, with three technical replicates). M) Proposed model summarizing the mechanism by which TRX2 regulates FOXO3a subcellular localization. Source data for the unedited raw immunoblots shown in Figure . All quantitative data are presented as means ± SEM. Statistical significance was determined by a two‐tailed unpaired Student's t ‐test. **** p < 0.0001.

    Article Snippet: Primary antibodies included: TRX2 (1:5000, Invitrogen, PA5‐81102), TRX2 (1:5000, Abcam, ab185544), TRAIL (1:2000, Proteintech, 66756‐1‐Ig), TRAIL (1:2000, Thermo Fisher Scientific, 1J5S5), FOXO3a (1:3000, Proteintech, 10849‐1‐AP), VDAC1 (1:5000, Proteintech, 10866‐1‐AP), HSP60 (1:5000, Proteintech,15282‐1‐AP), Histone H3 (1:5000, Proteintech, 68345‐1‐Ig), Lamin B1 (1:5000, Selleck, F0523), Flag (1:5000, Beyotime, AF2855), HA (1:5000, Proteintech, HRP‐66006), GAPDH (1:20000, Servicebio, ZB15004), and β‐Actin (1:20000, Servicebio, ZB15001).

    Techniques: Translocation Assay, Liquid Chromatography, Mass Spectrometry, Liquid Chromatography with Mass Spectroscopy, Analysis, Binding Assay, Tandem Mass Spectroscopy, Microscopy, Labeling, Isolation, Membrane, Fluorescence, Transfection, Control, Proximity Ligation Assay, Immunofluorescence, Staining, Co-Immunoprecipitation Assay, Construct, Docking Assay, Mutagenesis, Western Blot, Fractionation, Two Tailed Test

    Endothelial TRX2 restrains osteoclastogenesis and osteoporotic bone loss through FOXO3a‐mediated TRAIL signaling. A) Venn diagram analysis identifying candidate downstream targets. Overlap between aging‐up‐regulated genes and FOXO3a target genes identified Tnfsf10, which encodes TNF‐related apoptosis‐inducing ligand (TRAIL), as a candidate mediator. B) Bar graph showing the log 2 fold change of selected FOXO3a target genes in the GSE230665 dataset. C) Box plot showing normalized TRAIL expression in normal controls (NC) and patients with osteoporosis (OP) from the GSE230665 dataset. D) Western blot analysis of FOXO3a, TRAIL, and TRX2 protein levels in HEK293T cells transfected with pL‐vector, pL‐FOXO3a wild type (WT), pL‐FOXO3a ΔNLS mutant, or pL‐TRX2. β‐actin served as the loading control. E) Secreted TRAIL levels in the culture supernatants of the experimental groups in (D), as measured by enzyme‐linked immunosorbent assay (ELISA) (n = 4), with absorbance read at 450 nm. F) Representative TRAP staining images of osteoclasts derived from bone marrow‐derived macrophages (BMMs) isolated from Trx2 WT and Trx2 ECKO mice (n = 5). Scale bars, 400 µm. G, H) In vitro assessment of endothelial‐osteoclast crosstalk. (G) Left: schematic of the Transwell coculture system. Right: representative images of TRAP‐stained BMMs cocultured with control endothelial cells (shControl) or TRX2‐depleted endothelial cells (shTRX2) in the presence of immunoglobulin G (IgG) control or a TRAIL‐neutralizing monoclonal antibody (TRAIL‐mAb). Scale bars, 400 µm. (H) Quantification of the TRAP‐positive area fraction in (G) (n = 5). I‐K) In vivo rescue of TRX2 deficiency‐induced bone loss by TRAIL blockade. Representative 3D micro‐CT reconstructions of distal femurs from Trx2 WT and Trx2 ECKO mice treated with IgG or TRAIL‐mAb (I) (n = 4). Scale bars, 200 µm. Quantitative micro‐CT analysis of trabecular bone volume/tissue volume (BV/TV) (J) and trabecular number (Tb.N) (K). L, M) Histological evaluation of osteoclast formation in femoral sections. Representative images of TRAP‐stained femoral sections (L) and corresponding histomorphometric quantification of osteoclast surface per bone surface (Oc.S/BS) and osteoclast number per bone surface (Oc.N/BS) (M) (n = 4). Scale bars, 50 µm. Source data for the unedited raw immunoblots shown in Figure . Data in (C) are presented as means ± SEM, and statistical significance was determined by a two‐tailed unpaired Student's t ‐test. All other quantitative data are presented as means ± SEM, with statistical significance determined by one‐way ANOVA with Tukey's multiple‐comparisons test. * p < 0.05, ** p < 0.01, **** p < 0.0001.

    Journal: Advanced Science

    Article Title: Thioredoxin‐2 Alleviates Osteoporosis by Restraining FOXO3a Nuclear Translocation

    doi: 10.1002/advs.78304

    Figure Lengend Snippet: Endothelial TRX2 restrains osteoclastogenesis and osteoporotic bone loss through FOXO3a‐mediated TRAIL signaling. A) Venn diagram analysis identifying candidate downstream targets. Overlap between aging‐up‐regulated genes and FOXO3a target genes identified Tnfsf10, which encodes TNF‐related apoptosis‐inducing ligand (TRAIL), as a candidate mediator. B) Bar graph showing the log 2 fold change of selected FOXO3a target genes in the GSE230665 dataset. C) Box plot showing normalized TRAIL expression in normal controls (NC) and patients with osteoporosis (OP) from the GSE230665 dataset. D) Western blot analysis of FOXO3a, TRAIL, and TRX2 protein levels in HEK293T cells transfected with pL‐vector, pL‐FOXO3a wild type (WT), pL‐FOXO3a ΔNLS mutant, or pL‐TRX2. β‐actin served as the loading control. E) Secreted TRAIL levels in the culture supernatants of the experimental groups in (D), as measured by enzyme‐linked immunosorbent assay (ELISA) (n = 4), with absorbance read at 450 nm. F) Representative TRAP staining images of osteoclasts derived from bone marrow‐derived macrophages (BMMs) isolated from Trx2 WT and Trx2 ECKO mice (n = 5). Scale bars, 400 µm. G, H) In vitro assessment of endothelial‐osteoclast crosstalk. (G) Left: schematic of the Transwell coculture system. Right: representative images of TRAP‐stained BMMs cocultured with control endothelial cells (shControl) or TRX2‐depleted endothelial cells (shTRX2) in the presence of immunoglobulin G (IgG) control or a TRAIL‐neutralizing monoclonal antibody (TRAIL‐mAb). Scale bars, 400 µm. (H) Quantification of the TRAP‐positive area fraction in (G) (n = 5). I‐K) In vivo rescue of TRX2 deficiency‐induced bone loss by TRAIL blockade. Representative 3D micro‐CT reconstructions of distal femurs from Trx2 WT and Trx2 ECKO mice treated with IgG or TRAIL‐mAb (I) (n = 4). Scale bars, 200 µm. Quantitative micro‐CT analysis of trabecular bone volume/tissue volume (BV/TV) (J) and trabecular number (Tb.N) (K). L, M) Histological evaluation of osteoclast formation in femoral sections. Representative images of TRAP‐stained femoral sections (L) and corresponding histomorphometric quantification of osteoclast surface per bone surface (Oc.S/BS) and osteoclast number per bone surface (Oc.N/BS) (M) (n = 4). Scale bars, 50 µm. Source data for the unedited raw immunoblots shown in Figure . Data in (C) are presented as means ± SEM, and statistical significance was determined by a two‐tailed unpaired Student's t ‐test. All other quantitative data are presented as means ± SEM, with statistical significance determined by one‐way ANOVA with Tukey's multiple‐comparisons test. * p < 0.05, ** p < 0.01, **** p < 0.0001.

    Article Snippet: Primary antibodies included: TRX2 (1:5000, Invitrogen, PA5‐81102), TRX2 (1:5000, Abcam, ab185544), TRAIL (1:2000, Proteintech, 66756‐1‐Ig), TRAIL (1:2000, Thermo Fisher Scientific, 1J5S5), FOXO3a (1:3000, Proteintech, 10849‐1‐AP), VDAC1 (1:5000, Proteintech, 10866‐1‐AP), HSP60 (1:5000, Proteintech,15282‐1‐AP), Histone H3 (1:5000, Proteintech, 68345‐1‐Ig), Lamin B1 (1:5000, Selleck, F0523), Flag (1:5000, Beyotime, AF2855), HA (1:5000, Proteintech, HRP‐66006), GAPDH (1:20000, Servicebio, ZB15004), and β‐Actin (1:20000, Servicebio, ZB15001).

    Techniques: Analysis, Expressing, Western Blot, Transfection, Plasmid Preparation, Mutagenesis, Control, Enzyme-linked Immunosorbent Assay, Staining, Derivative Assay, Isolation, In Vitro Evaluation, In Vivo, Micro-CT, Tissue, Two Tailed Test

    Mechanistic illustration of endothelial TRX2–FOXO3a–mediated TRAIL secretion and osteoclastogenesis in osteoporotic bone loss. In the healthy skeletal vascular niche, TRX2 binds FOXO3a through a redox‐sensitive Cys90–Cys31 disulfide interface, retaining FOXO3a at the mitochondrial outer membrane and preventing its nuclear translocation in BVECs. By contrast, in the osteoporotic state, TRX2 loss or oxidative stress disrupts this disulfide‐mediated interaction, allowing FOXO3a nuclear translocation and activation of the TRAIL promoter. Increased endothelial TRAIL secretion remodels the extracellular vascular–skeletal niche by promoting osteoclastogenesis, enhancing osteoclastic bone resorption, and suppressing osteoblast‐associated osteogenesis, thereby driving osteoporosis progression.

    Journal: Advanced Science

    Article Title: Thioredoxin‐2 Alleviates Osteoporosis by Restraining FOXO3a Nuclear Translocation

    doi: 10.1002/advs.78304

    Figure Lengend Snippet: Mechanistic illustration of endothelial TRX2–FOXO3a–mediated TRAIL secretion and osteoclastogenesis in osteoporotic bone loss. In the healthy skeletal vascular niche, TRX2 binds FOXO3a through a redox‐sensitive Cys90–Cys31 disulfide interface, retaining FOXO3a at the mitochondrial outer membrane and preventing its nuclear translocation in BVECs. By contrast, in the osteoporotic state, TRX2 loss or oxidative stress disrupts this disulfide‐mediated interaction, allowing FOXO3a nuclear translocation and activation of the TRAIL promoter. Increased endothelial TRAIL secretion remodels the extracellular vascular–skeletal niche by promoting osteoclastogenesis, enhancing osteoclastic bone resorption, and suppressing osteoblast‐associated osteogenesis, thereby driving osteoporosis progression.

    Article Snippet: Primary antibodies included: TRX2 (1:5000, Invitrogen, PA5‐81102), TRX2 (1:5000, Abcam, ab185544), TRAIL (1:2000, Proteintech, 66756‐1‐Ig), TRAIL (1:2000, Thermo Fisher Scientific, 1J5S5), FOXO3a (1:3000, Proteintech, 10849‐1‐AP), VDAC1 (1:5000, Proteintech, 10866‐1‐AP), HSP60 (1:5000, Proteintech,15282‐1‐AP), Histone H3 (1:5000, Proteintech, 68345‐1‐Ig), Lamin B1 (1:5000, Selleck, F0523), Flag (1:5000, Beyotime, AF2855), HA (1:5000, Proteintech, HRP‐66006), GAPDH (1:20000, Servicebio, ZB15004), and β‐Actin (1:20000, Servicebio, ZB15001).

    Techniques: Membrane, Translocation Assay, Activation Assay